Valuation
- Market cap
- 14,178,914,000
- Revenue TTM
- $814,760,000
- Net income TTM
- $-258,000,000
- PE ratio
- 126.57
- Forward PE
- 64.26
- Profit margin
- -31.67%
- Debt to equity
- 0.31
Trading
- Volume
- 641,400
- Avg volume
- 678,532
- Day's range
- $225.20 – $229.02
- Shares out
- 62,377,000
- Stochastic %K
- 37%
- Beta
- 0.38
- Analysts
- Strong Sell
- Price target
- $314.75
Company profile
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipe...
Show more
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 45 70 22 22 44
- Website
- https://ascendispharma.com
- Address
- Tuborg Boulevard 12, Hellerup, Denmark
Latest news
No headlines yet.
